Professional Background:

Greg Santamaria is the Co-Founder, Director and CEO of Cyclotek. Over multiple decades Greg has gained extensive experience in business development and operations, asset management and finance structuring. Greg holds several board and consultancy positions within private companies in the fields of healthcare, manufacturing, wholesale and finance. Since 2016 Greg has been CEO of the Cyclotek group, which compounds and distributes diagnostic and therapeutic radiopharmaceuticals across Australia and New Zealand.

Research Interests:

Throughout his time at Cyclotek, Greg has executed a number of research projects in

collaboration with industry and academic partners. Between 2005 and 2012, Greg led the Cooperative Research Centre for Biomedical Imaging Development, an 8-year project that aimed to develop targeted radiopharmaceuticals for the diagnostic imaging of cancer, culminating in three first in human clinical trials. With his Innovation team, Greg now manages multiple research and development programs that aim to translate novel radiolabelling methods and targeting vectors into commercially viable theranostic products.